Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Notes Tables
Notes Details

Sponsored Research and License Agreements (Details)

v3.4.0.3

Sponsored Research and License Agreements (Details) - USD ($)	1 Months Ended				3 Months Ended
	Sep. 30, 2015	Aug. 31, 2015	Mar. 31, 2015	Feb. 28, 2015	Mar. 31, 2016	Sep. 30, 2015	Mar. 31, 2015
Collaborative Arrangement
Collaborations
Maximum amount of contingent payments receivable					$ 533,600,000
Specified Development Events \| Collaborative Arrangement
Collaborations
Maximum amount of contingent payments receivable					150,500,000
Specified Regulatory Events \| Collaborative Arrangement
Collaborations
Maximum amount of contingent payments receivable					345,600,000
Specified Product Launch Events \| Collaborative Arrangement
Collaborations
Maximum amount of contingent payments receivable					37,500,000
Bristol-Myers Squibb Company
Collaborations
Noncreditable and nonrefundable upfront payment by BMS			$ 30,000,000
Deferred revenue related to upfront payment				$ 30,000,000	8,600,000
Revenue recognized					4,800,000		$ 2,100,000
Bristol-Myers Squibb Company \| Research Activities
Collaborations
Revenue recognized					$ 195,000		$ 106,000
Bristol-Myers Squibb Company \| Minimum
Collaborations
Contingent payments				$ 309,000,000
Aclaris
Collaborations
Upfront fee received	$ 8,000,000
Contingent payments		$ 80,000,000
Revenue recognized						$ 8,000,000

- Definition

Represents the amount of deferred revenue as of balance sheet date related to upfront payment under the collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementDeferredRevenueRelatedToUpfrontPayment
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the maximum amount of pre-specified contingent payments receivable under the collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementMaximumAmountOfContingentPaymentReceivable
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the revenue recognized during the period under the terms of sponsored research and license agreements.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementRevenueRecognized
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementUpfrontFeeReceived
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the additional contingent payments by BMS.

+ References

No definition available.

+ Details

Name:	rigl_ContingentPaymentsUnderAgreement
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the noncreditable and nonrefundable upfront payment by BMS.

+ References

No definition available.

+ Details

Name:	rigl_NonCreditableAndNonRefundableUpfrontPayment
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedDevelopmentEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedRegulatoryEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedProductLaunchEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rigl_BristolMyersSquibbCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_ResearchActivitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rigl_AclarisTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: